panitumumab + irinotecan hydrochloride + fluorouracil + leucovorin calcium

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Mucinous Adenocarcinoma of the Colon

Conditions

Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer

Trial Timeline

Feb 1, 2013 → Aug 6, 2018

NCT ID

NCT01814501

About panitumumab + irinotecan hydrochloride + fluorouracil + leucovorin calcium

panitumumab + irinotecan hydrochloride + fluorouracil + leucovorin calcium is a phase 2 stage product being developed by Amgen for Mucinous Adenocarcinoma of the Colon. The current trial status is completed. This product is registered under clinical trial identifier NCT01814501. Target conditions include Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01814501	Phase 2	Completed	Feb 1, 2013	Aug 6, 2018	Mucinous Adenocarcinoma of the Colon

Competing Products

2 competing products in Mucinous Adenocarcinoma of the Colon

See all competitors

Product	Company	Stage	Hype Score
cetuximab	Eli Lilly	Phase 2	52
aflibercept + oxaliplatin + leucovorin + fluorouracil	Sanofi	Phase 2	51

Other Products from Amgen